PRAF2 and hepatocellular carcinoma: It has been reported that overexpression of PRAF2 shows a significantly correlation with malignant clinical characteristics and predicts poor prognostic outcome in malignant glioma, neuroblastoma and hepatocellular carcinoma [18–20].